Log in
A new family of antiviral agents, bicyclic nucleoside analogues (BCNAs), discovered in Cardiff University has led to a highly potent anti-VZV (shingles) molecule, FV-100. On a worldwide basis more than two million patients are affected by shingles annually. FV-100 has successfully completed Phase II clinical trials, showing it is safe, potent and effective and with clinical advantages over the current standard of care. FV-100 has received more than $30 million in R&D investment, generating patents and creating highly skilled jobs in the UK and the USA, with the parent company currently valued at $397 million. It will enter registration trials in late 2013.
Economic impact is claimed through the growth of the biopharmaceutical spin-out company Q Chip Ltd. During the REF period, this has created 19 new jobs, £7.5M investment, a new Dutch subsidiary (Q Chip BV), and staged-payment, six figure contract sales to four major international pharmaceutical companies.
Q Chip has generated over £928K in contract sales from the pharmaceutical industry from 2008-2012, with further sales of over £1M projected in 2013-14.
Originally established by Professor David Barrow in 2003 from his micro technology research, Q Chip has developed new processes and miniaturised equipment to encapsulate materials, including drugs, within uniform polymeric microspheres as injectable therapeutics.
Cardiff University research in 1997-2008 resulted in the development of a family of novel far-red fluorescent dyes that stain the DNA of cells. The leading live cell dye DRAQ5™ is now utilised in a wide range of laboratory assays, transforming practice in clinical, commercial and research sectors. Smith co-founded the multi-award-winning start-up company Biostatus Ltd in 2001 to undertake product development. Commercial impact post-2008 has been the generation of over $3.2 million in sales revenue enabling job creation, direct funding of UK academic research positions and creation of new technology start-up companies. Used in over 3,500 research, pharmaceutical and clinical organisations, DRAQ™ technology has global reach.
Producers of dietary supplements have historically lacked scientific rigour when advertising the health benefits of their products. Researchers at Cardiff University have addressed this problem in relation to omega-3 polyunsaturated fatty acids (PUFAs). They identified a family of enzymes (aggrecanases) as key players in the onset of arthritis, knowledge subsequently used to identify a specific subset of omega-3-PUFAs with beneficial activity in a canine arthritis model. This led to novel patents and product development in both the pet food and human dietary supplement markets. These include the patented use of omega-3 PUFAs in Hills'® Prescription Diet® range and the development and marketing of Seven Seas' `JointCare' products.
Cardiff University's research in acoustic emission monitoring and refined data analysis has been applied to large, complex structures and has subsequently transformed the inspection processes of concrete and steel bridges. This has been commercialised by Mistras Group Ltd. to provide a safer, more reliable and progressive means of bridge monitoring, enabling the company to acquire a global reputation and increase its turnover to £7.5M per year — £5M relating to Cardiff research. Cardiff's innovations have had major international impacts (in UK, Europe, India and USA) through:
Cardiff University, through developing and patenting a commercially viable synthetic route to a catalyst, has enabled the application of a new process, the Alpha Process, for the production of methyl methacrylate (MMA), a key commodity precursor to Perspex. The Alpha Process has had economic and environmental impacts.
Lucite International, the world's leading MMA producer, has invested in major Alpha Process production facilities in Singapore and Saudi Arabia, benefitting from a production route which is more efficient, more reliable and cheaper than conventional routes.
The Alpha Process also brings environmental benefits, as it does not rely on the use of corrosive and toxic feedstocks, such as hydrogen cyanide, which are associated with conventional MMA processes.
Research and Development activity at Cardiff University's Astronomy Instrumentation Group (AIG) has been commercialised and made available to the international market. Sales have been made to fields including bio-molecular spectroscopy for health science, plasma fusion diagnostics for sustainable energy, and remote atmospheric sensing. This has resulted in economic impact through:
3D scanning technology has enabled multiple opportunities for innovation in diverse areas such as manufacturing, design, and the arts. However, full utilisation of this technology requires not just the scanning hardware, but accompanying software that can build meaningful, editable models. This development has been pioneered by research conducted in the School of Computer Science and Informatics, at Cardiff University. Innovative algorithms for reverse engineering and digital shape reconstruction were devised that enabled the reconstruction of complex computer aided design (CAD) models from data captured by 3D scanners. The algorithms have been endorsed by Geomagic Inc, a market leading American software corporation (recently acquired by 3D Systems), that has subsidiaries in Europe and Asia and global distributors, and incorporated into their software product suite. This is accessed by nearly 10,000 licensed users worldwide, who have applied the product for industrial applications including aerospace and automotive engineering, product design, cultural heritage preservation, and healthcare. Accordingly, the impacts claimed are twofold: a) economic gain manifesting in the benefits to Geomagic and a plethora of end users who have utilised the software, b) impact on practitioners and professional services in diverse domains.
ProTide technology, discovered by the McGuigan team at Cardiff University, is a pro-drug strategy with proven capacity to generate new drug candidates for nucleoside-based antiviral and anti- cancer indications. In the assessment period the McGuigan team has attracted more than £2 million direct research funding through sustained collaborations on ProTide technology with global pharmaceutical companies and smaller biotech firms in the USA and Europe. In the same period, either through working directly with Cardiff or by independent adoption of McGuigan's research, eight ProTide entities have progressed to clinical trials as cancer, HIV and hepatitis C treatments. The technology is demonstrating significant commercial impact for companies with ProTide-based drug candidates.
Platinum Group Elements (PGE) are critical strategic metals because of their unrivalled applications in catalysts, fuel cells and electronics and cancer therapies. Research and analytical methods developed at Cardiff have impacted on exploration for new PGE deposits, and more efficient processing of PGE ores by international mining companies. A key milestone between 2009 and 2012 was the discovery of a 3 billion year old giant impact crater in West Greenland. This discovery is of major economic significance because all craters previously found in this size class are associated with multi-billion dollar mineral and/or hydrocarbon resources. It led to an intellectual property transaction worth CDN$ 2.1 million and discovery of nickel and PGE deposits in Greenland by North American Nickel Incorporated.